Celera Genomics Group, Pharmacyclics deal

PCYC acquired CRA's therapeutics programs for $2 million in cash and 500,000-1 million PCYC shares. Acquired assets include an HDAC inhibitor program in Phase I trials for refractory solid tumors; a ...